The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >
Hybridization-based target enrichment panel with our intrinsic probe design, rebalancing, and molecular barcode technologies to efficiently analyze not only hard-to-capture areas but also challenging samples, such as damaged DNA or RNA.
View Detail >
End-to-end customized target enrichment panel with assay optimization, validation and even complete BI support. Over 1,000 custom panels developed world-wide. White-labeled customized product for business expansion also available.
View Detail >
The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >
The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >
End-to-end customized target enrichment panel with assay optimization, validation and even complete BI support. Over 1,000 custom panels developed world-wide. White-labeled customized product for business expansion also available.
View Detail >
Providing NGS-based diagnostics solutions for biopharma companies. Celemics can develop and deliver a flexible customization and commercialization services while maintaining the market-leading performance for our clients interested in clinical and companion diagnostics.
View Detail >
Tailored-fit customized assay development from designing to validation run; including not only the custom panel design but also species-specific or sequencer-specific blockers, followed by reagent conditioning to optimize the individual experiment and sequencer.
View Detail >
The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >
Find useful information, insights and tools for your Celemics’ products and services
View Detail >
Explore the most up-to-date publications featuring Celemics’ products and services
View Detail >
Sharing interesting stories about the world of NGS and how Celemics delivers the innovative NGS solutions to the world of science.
View Detail >
Find useful information, insights and tools for your Celemics’ products and services
View Detail >
Stay up-to-date with the latest updates on our activities, events and achievements
View Detail >
Let’s change the NGS market together – our global presence and partners world-wide
View Detail >
Waiting for your experience with Celemics, an innovative leader in NGS industry
View Detail >Liquid Biopsy
Clin Chem Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden Lee KS, Seo J, Lee CK, Shin S, Choi Z, Min…
Br J Cancer Dynamic changes in longitudinal circulating tumour DNA profile during metastatic colorectal cancer treatment Kim S, Lim Y, Kang JK, Kim HP, Roh H, Kim SY, et al.…
World Journal of Clinical Cases Detection of EGFR-SEPT14 fusion in cell-free DNA of a patient with advanced gastric cancer: A case report Kim B, Kim Y, Park I, Cho JY,…
Investigative and clinical urology Genomic mutation profiling using liquid biopsy in Korean patients with prostate cancer: Circulating tumor DNA mutation predicts the development of castration resistance </h4 > Yu J,…
Sci Rep Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR Lim Y, Kim S, Kang JK, Kim HP, Jang H, Han H, et al.…
Scientific Reports MLH1 single‑nucleotide variant in circulating tumor DNA predicts overall survival of patients with hepatocellular carcinoma Kim SS, Eun JW, Choi JH, Woo HG, Cho HJ, Ahn HR, et…
PloS one Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing Kang JK, Heo S, Kim HP, Song SH, Yun H, Han SW, et al. Liquid…
Scientific Reports Urinary Exosomal and cell-free DNA Detects Somatic Mutation and Copy Number Alteration in Urothelial Carcinoma of Bladder Lee DH, Yoon H, Park S, Kim JS, Ahn YH, Kwon…
